Beta-adrenoceptor blocking drugs

Adverse effects associated with practolol have been collectively described as the oculomucocutaneous syndrome. The incidence of the syndrome is small but the seriousness of the tissue damage has tended to overshadow this incidence. Practolol was marketed in 1970, and by the end of 1975 the drug had been used for some 300,000 patient years in the UK, and around one million worldwide. By October 1974, 164 cases were known, and in November 1977, the total had reached 915 (Nicholls 1978). The drug was withdrawn in 1976. It is now reasonably certain that none of the other jS-blockers in clinical use has so far induced an oculomuco-cutaneous-type syndrome. 

---

Brismar, K Mogensen, L. Wetterberg, L. (1987). Depressed melatonin secretion in patients with nightmares due to beta-adrenoceptor blocking drugs. Acta Med. Scand. 221, 155-8. 

Verapamil Beta-adrenoceptor blocking drugs Asystole, hypotension. 

Adrenaline, noradrenaline Beta-adrenoceptor blocking drugs Potentiation of hypertensive effect. 

Clonidine Beta-adrenoceptor blocking drugs Increased risk of clonidine withdrawal hypertension. 

Wright AD, Barber SG, Kendall MJ, Poole PH. Beta-adrenoceptor-blocking drugs and blood sugar control in diabetes mellitus. BMJ 1979 1(6157) 159-61. 

Ondrias, K., Stasko, A., Marko, V., and Nosal, R. (1989), Influence of beta-adrenoceptor blocking drugs on lipid-protein interaction in synaptosomal membranes. An ESR study, Chem. Biol. Interact., 69, 87-97. 

McDevitt DG. Differential features of beta-adrenoceptor blocking drugs for therapy. Laragh J, Buhler F, editors. Frontiers in Hypertension Research. New York Springer Verlag, 1981 473. 

McDevitt DG. Beta-adrenoceptor blocking drugs and partial agonist activity. Is it clinically relevant Drugs 1983 25(4) 331-8. 

Greenblatt DJ, Koch-Weser J. Clinical toxicity of propranolol and practolol a report from the Boston Collaborative Drug Surveillance Program. Avery GS, editor. Cardiovascular Drugs. Vol 2. Beta-Adrenoceptor Blocking Drugs, Chapter VIII. Sydney Adis Press 1977 179. 

Aellig WH. Pindolol—a beta-adrenoceptor blocking drug with partial agonist activity clinical pharmacological considerations. Br J Clin Pharmacol 1982 13(Suppl 2) S187-92. 

Patel L, Turner P. Central actions of beta-adrenoceptor blocking drugs in man. Med Res Rev 1981 1(4) 387-410. 

Pryor JP, Castle WM, Dukes DC, Smith JC, Watson ME, Williams JL. Do beta-adrenoceptor blocking drugs cause retroperitoneal fibrosis BMJ (Clin Res Ed) 1983 287(6393) 639 1. 

Lewis RV, McDevitt DG. Adverse reactions and interactions with beta-adrenoceptor blocking drugs. Med Toxicol 1986 1(5) 343-61. 

Kendall MJ, Beeley L. Beta-adrenoceptor blocking drugs adverse reactions and drug interactions. Pharmacol Ther 1983 21(3) 351-69. 

Lemmer B, Ohm T, Winkler H Determination of the beta-adrenoceptor blocking drug sotalol in plasma and tissues of the rat by high-performance liquid chromatography with ultraviolet detection. 7. Chromatogr. 1984 309 187-192. 

---